Wave Life Sciences has discontinued its experimental drug WVE-004, an antisense oligonucleotide designed to silence the toxic repeat RNA produced by a mutation in the C9orf72 gene, the most common genetic cause of frontotemporal dementia and amyotrophic lateral sclerosis. The company's own topline results, announced May 23, 2023, showed that despite reducing a disease biomarker, the drug produced no measurable clinical benefit after 24 weeks, and the trial's registration on ClinicalTrials.gov was updated in October 2023 to record the study as terminated.

The drug was tested in FOCUS-C9 (NCT04931862), a Phase 1b/2a, randomized, double-blind, placebo-controlled trial that enrolled 35 people with C9orf72-associated ALS or frontotemporal dementia at sites worldwide. Participants received WVE-004 or placebo by injection into the spinal fluid, in single or repeated doses, starting in June 2021. The drug was engineered to bind and degrade only the mutant, repeat-containing RNA transcript made from the expanded C9orf72 gene, while leaving the normal copy of the gene's product intact, an approach meant to avoid the broader effects of shutting down the gene entirely.

On that biological target, the drug worked: Wave reported large, durable reductions in poly(GP), a dipeptide repeat protein in spinal fluid used as a marker of C9orf72 pathology, with a peer reviewed commentary in the journal Brain citing reductions of 48 to 51 percent. But that biomarker change did not translate into a clinical effect. The company found no difference between drug and placebo on the ALS Functional Rating Scale or on the CDR plus NACC FTLD scale, a staging tool used to track frontotemporal dementia, and reductions in poly(GP) did not correlate with any functional outcome. Based on those findings, Wave stopped the FOCUS-C9 study and its open label extension.

The result places WVE-004 alongside BIIB078, a similarly designed C9orf72 antisense drug from Biogen and Ionis that was discontinued for the same reason: strong engagement of the biomarker without a matching clinical effect. The Brain commentary, published in 2024, used both failures to argue that poly(GP) reduction alone may not be a reliable stand-in for clinical benefit in future C9orf72 trials, and that other approaches targeting the repeat RNA, or earlier points in disease progression, remain to be tested.